Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NEONC TECHNOLOGIES HOLDINGS, INC. Chief Clinical Officer Yousha Neman-Ebrahim bought 500 shares of Common Stock in an open-market purchase at $4.88 per share. After this transaction, the executive directly owns 134,760 shares, so the new purchase represents a small addition to an already sizable position.
NEONC Technologies Holdings CFO Garnett Keithly reported an open-market purchase of 300 shares of common stock at $5.38 per share on April 15, 2025. Following this transaction, he directly holds 241,200 common shares.
Separately, the filing lists an indirect holding of 44,053 common shares owned by HCWG LLC. Keithly is a beneficial owner of these shares through his role as sole member of The Hilkiah Group LLC, which holds a 4.3% interest in HCWG LLC.
NeOnc Technologies Holdings, Inc. is raising capital through a series of private placements of common stock and five-year warrants. Across four Securities Purchase Agreements, the company has agreed to issue shares at $7.20 per share with accompanying warrants exercisable at $9.00 per share.
The latest, fourth agreement dated April 20, 2026 covers up to 406,694 shares and related warrants, with an initial closing of 277,777 shares and 277,777 warrants for approximately $2 million. Earlier agreements in January, February and March 2026 included multiple closings with institutional and other investors.
The company intends to use the net proceeds to fund NEO216 preclinical trials. The securities were issued under an exemption from registration provided by Section 4(a)(2) of the Securities Act, and NeOnc will file a resale registration statement for the shares and warrant shares within ten days of the initial closing under the fourth agreement.
Neonc Technologies Holdings, Inc. president Amir F. Heshmatpour reported an open-market purchase of 10,000 shares of common stock at $4.90 per share. The trade on April 23, 2026 increased his direct holdings to 3,052,000 shares.
He also reports indirect ownership interests, including 3,714,020 shares held by AFH Holdings & Advisory, LLC, 550,000 shares held by KIG LLC, and 256,120 shares representing his proportionate interest in HCWG LLC, with certain family and spousal holdings subject to beneficial ownership disclaimers.
NeOnc Technologies Holdings, Inc. reported that its Chairman and CEO, Amir Heshmatpour, recently bought approximately $300,000 of NTHI stock, signaling management’s confidence in the company. The update also explains the components of the company’s 2025 net loss and its current cash use.
For 2025, NeOnc recorded a net loss of about $62 million, with roughly 73% tied to non-cash stock-based compensation and one-time listing-related advisory fees. These non-cash and non-recurring items totaled $45.2 million, leaving normalized ongoing cash operating expenses of about $10.1 million. NeOnc also raised approximately $13.0 million in a Q1 2026 private placement, using part of the proceeds to repay short-term convertible debt and settle accrued obligations, and highlighted a reconciliation showing 2025 core operating cash burn of roughly $10.1 million.
NeOnc Technologies Holdings, Inc. is registering 680,558 shares of Common Stock for resale by selling stockholders. The 680,558 shares consist of 340,279 currently issued shares and 340,279 shares issuable upon exercise of Warrants exercisable at $9.00 per share and expiring five years from issuance. The resale registration covers shares issued in several private placement closings and is being filed to satisfy registration rights granted to the selling holders. The Company will not receive proceeds from resales by the selling holders; it would receive proceeds only if Warrants are exercised for cash rather than on a cashless basis. Common stock outstanding was 24,911,482 shares as of April 8, 2026, and the last reported Nasdaq sale price was $5.37 per share.
NEONC Technologies Holdings' Chief Accounting Officer David Suh Jr. reported recent stock activity. On April 9, 2026, he made an open-market purchase of 200 shares of common stock at $5.00 per share, bringing his direct holdings to 111,866 shares.
On March 1, 2026, he was granted an aggregate 170,000 shares of restricted common stock under the company’s 2023 Equity Incentive Plan. Of these, 53,333 shares vested immediately, 58,333 shares are scheduled to vest on the one-year anniversary of the grant, and the remaining shares are performance-based, with the final number deliverable depending on achievement of specified performance criteria.
NEONC TECHNOLOGIES HOLDINGS, INC. executive David Suh Jr., the Chief Accounting Officer, has filed an initial Form 3 as a reporting person for the company’s stock. The filing shows no reported transactions or holdings in the issuer’s securities at this time based on the provided data.
NeOnc Technologies Holdings, Inc. is registering 680,558 shares of Common Stock for resale by selling stockholders, consisting of 340,279 issued shares and 340,279 shares issuable upon exercise of warrants. The registration covers resales by holders who acquired shares and five-year warrants in private placements in January–March 2026. The Company will not receive proceeds from resales; it may receive exercise proceeds if warrants are exercised. Shares outstanding were 24,911,482 as of April 8, 2026. The prospectus discloses outstanding warrants to purchase 1,815,528 shares exercisable at $9.00 per share and notes recent operating losses and tax liabilities.